The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•21 April 2026•

1 min read

Amneal Pharmaceuticals Reports Positive Phase 4 Data for Parkinson’s Drug CREXONT

Key Facts

1Phase 4 data showed a 3.07-hour increase in daily 'Good On' time for patients switching from RYTARY to CREXONT.

2Amneal Pharmaceuticals announced the results during the 2026 American Academy of Neurology (AAN) Annual Meeting.

Amneal Pharmaceuticals has announced positive interim Phase 4 data from its ELEVATE-PD study evaluating CREXONT, a treatment for Parkinson's disease. The data, presented at the 2026 American Academy of Neurology (AAN) Annual Meeting, revealed a significant 3.07-hour increase in daily 'Good On' time for patients switching from RYTARY to CREXONT. Furthermore, the study demonstrated meaningful improvements in motor functions and a substantial reduction in patient 'Off' time. These results aim to establish the clinical superiority of CREXONT in enhancing the daily management of Parkinson's symptoms. Such strong clinical outcomes are expected to bolster investor confidence in the company's product pipeline and long-term revenue potential. This development underscores AMRX's strategic focus on advancing therapeutic solutions within the biotechnology sector.